This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

About MAXALT® (rizatriptan)

Updated on 15/03/2018

MIGRAINE

MAXALT 10 mg:

  • Provides relief that lasts up to 24 hours post dose1,5
  • Provides pain relief from 2 hours1 and is available in a formulation that patients prefer4,5

Prescribe MAXALT 10 mg for those aged 18 and over for the acute treatment of the headache phase of migraine attacks with or without aura

Before prescribing MAXALT or MAXALT Melt, please consult the Summary of Product Characteristics below:

MAXALT Melt 10 mg Oral Lyophilisate packaging includes an outer box, plastic container and individual packet

Efficacy of MAXALT


Relief up to 24 hours | Efficacy from 30 minutes | Efficacy post-sumatriptan failure

Efficacy that lasts up to 24 hours post dose 6,7

A prospective study in 297 patients, 231 of whom completed diaries, showed that in 81% of migrane attacks, patients only needed one MAXALT 10 mg tablet per attack in a 24 hour period. 6

In an open-label community survey with other medication permitted.

Graph showing percentage of attacks treated with one rizatriptan tablet

Adapted from Pascual J et al 2002

Study design
Study design
Study design

References

  1. Ferrari MD, Roon Kl et al. Oral triptans (serotonin 5-HT1B/1D agonists) in acute treatment of migraine. Lancet 2001;358:1668-1675.
  2. Ferrari MD, Goadsby PJ et al. Triptans (serotonin, 5-HT 1B1D agonists) in migraine detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-658.
  3. Gobel H, Heinze A et al. Efficacy and tolerability of rizatriptan 10 mg in migraine: Experience with 70,527 patients episodes. Headache 2001;41:264-270.
  4. Ahrens SP, Farmer MV et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalagia 1999;19:525-30.
  5. MAXALT 10 mg Summary of Product Characteristics.
  6. Pascual J, Fit B et al. Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain. Headache 2002;42:93-98.
  7. Seeburger JL, Taylor FR et al. Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. Cephalalgia. 2011 May; Epub 2010 Nov 15; 31(7): 786-96.

Supporting documentation

MAXALT 5 mg and 10 mg Tablets
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

MAXALT 10 mg Oral Lyophilisates
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

NEUR-1247540-0000 | Date of Preparation: March 2018